Search

Displaying results 1441 - 1450 of 7452 in total
  1. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). … SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs.

    Categories: Antidepressive Agents Indicated for Depression
  2. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    Etidronic acid is a first generation bisphosphonate similar to clodronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has de...

    Categories: Drugs for Treatment of Bone Diseases
  3. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. … March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for

  4. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO.

    Mixtures: Complete Multivitamins and Minerals for Children
  5. Drug

    Tirasemtiv

    go.drugbank.com/drugs/DB12209
    Investigational

    Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.

  6. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … [A218171, A218176, A229988] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping to produce truncated BMD-like dystrophin proteins, which restore

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]

  8. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]

  9. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.

  10. Drug

    Mechlorethamine

    go.drugbank.com/drugs/DB00888
    ApprovedInvestigational

    The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL

    Categories: Compounds used in a research, industrial, or household setting